PLK1 and glioblastoma: A single intracerebral injection of CRISPR–LNPs against PLK1 (sgPLK1–cLNPs) into aggressive orthotopic glioblastoma enabled up to ≈70% gene editing in vivo, which caused tumor cell apoptosis, inhibited tumor growth by 50%, and improved survival by 30%.